Register Now
Download the Brochure
Home
Leadership In Follow-On Innovation
The 13th Annual Business of Biosimilars & Generic Drugs is the world's largest development and commercialization event for the follow-on biopharmaceutical industry, bringing drug development and market access executives the tools to compete and maximize pipeline profitability in today's global competitive environment.
INDUSTRY EXPERTS
 |
 |
 |
Strategic Partnerships for Navigating the Brave New Globalized Life Science Industry G. Steven Burrill | CEO | BURRILL & COMPANY |
Outlook and Strategic Impact of
U.S. Biosimilars Approval Pathway Carrie Burke | Director of Government Affairs | SHIRE |
Turn Antitrust Laws to Your Advantage in the Generic and Biosimilar Market Suzanne Munck | Chief Counsel for Intellectual Property | FTC |
 |
 |
 |
Overview of Biosimilar Trends In BRIC Countries Alex Kudrin | Medical Director | TAKEDA PHARMACEUTICALS |
Best Pratices in Portfolio Management During Patent Exchange Process Mark Hyman | Assistant General Counsel, Litigation & IP | HUMAN GENOME SCIENCES |
Establish R&D Methods and Timetables that will
Streamline your Expansion into New Markets Andrew Shaw |Senior Director, PKDM | MYLAN LABS |
Guided by its 13 years of history in assembling top-notch expertise about follow-on biopharmaceuticals, this year's event will give you the skills to:
- Assure biosimilar approval through better understanding of recent FDA guidelines
- Capitalize on new markets by learning from every sector of the follow-on biopharma industry
- Revolutionize your pipelines through state-of-the-art strategic partnerships for product development
- Maximize your profits by improving physician and patient uptake of your product class